Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review

References

• Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):7–18. doi:10.1111/liv.14093.30882996
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590.31912902
   PubMed Web of Science ®Google Scholar
• Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol. 2007;19(8):615–617. doi:10.1097/MEG.0b013e328224b935.17625428
   PubMed Web of Science ®Google Scholar
• Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10(Suppl 4):308–311. doi:10.1093/annonc/10.suppl_4.S30810436847
   PubMed Web of Science ®Google Scholar
• Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72(1):95–103. doi:10.1016/j.jhep.2019.09.007.31536748
   PubMed Web of Science ®Google Scholar
• Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173–184. doi:10.1002/hep.24351.21488076
   PubMed Web of Science ®Google Scholar
• Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10(2):77–82. doi:10.1080/13651820801992641.18773060
   PubMed Web of Science ®Google Scholar
• Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019;19(1):185. doi:10.1186/s12885-019-5391-0.30819129
   PubMed Web of Science ®Google Scholar
• Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017;116:11–31. doi:10.1016/j.critrevonc.2016.11.012.28693792
   PubMed Web of Science ®Google Scholar
• Mukkamalla SKR, Naseri HM, Kim BM, Katz SC, Armenio VA. Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States. J Natl Compr Canc Netw. 2018;16(4):370–376. doi:10.6004/jnccn.2017.7056.29632056
   PubMed Web of Science ®Google Scholar
• Van Dyke AL, Shiels MS, Jones GS, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999–2013. Cancer. 2019;125(9):1489–1498. doi:10.1002/cncr.31942.30645774
   PubMed Web of Science ®Google Scholar
• Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594–599. doi:10.1634/theoncologist.2015-0446.27000463
   PubMed Web of Science ®Google Scholar
• Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806–813. doi:10.1016/s0168-8278(02)00297-0.12445422
   PubMed Web of Science ®Google Scholar
• Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010;2(12):419–427. doi:10.4254/wjh.v2.i12.419.21191517
   PubMedGoogle Scholar
• Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3rd English edition. J Hepatobiliary Pancreat Sci. 2015;22(3):181–196. doi:10.1002/jhbp.21125691463
   PubMed Web of Science ®Google Scholar
• Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol. 2003;181(3):819–827. doi:10.2214/ajr.181.3.181081912933488
   PubMed Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–280. doi:10.1038/nrgastro.2016.5127095655
   PubMed Web of Science ®Google Scholar
• Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):22–34. doi:10.21037/hbsn.2016.11.0428261592
   PubMed Web of Science ®Google Scholar
• Adeva J, Sangro B, Salati M, et al. Medical treatment for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):123–142. doi:10.1111/liv.1410030892822
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. doi:10.1038/s41575-020-0310-z32606456
   PubMed Web of Science ®Google Scholar
• Wang X, Yu GY, Chen M, Wei R, Chen J, Wang Z. Pattern of distant metastases in primary extrahepatic bile-duct cancer: a SEER-based study. Cancer Med. 2018;7(10):5006–5014. doi:10.1002/cam4.177230277653
   PubMed Web of Science ®Google Scholar
• Yan X, Wang P, Zhu Z, et al. Site-specific metastases of intrahepatic cholangiocarcinoma and its impact on survival: a population-based study. Future Oncol. 2019;15(18):2125–2137. doi:10.2217/fon-2018-084631161810
   PubMed Web of Science ®Google Scholar
• Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology. 2018;18(8):862–867. doi:10.1016/j.pan.2018.09.00430249386
   PubMed Web of Science ®Google Scholar
• Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvise M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98–107. doi:10.1111/liv.14086
   PubMed Web of Science ®Google Scholar
• Sainani NI, Catalano OA, Holalkere NS, Zhu AX, Hahn PF, Sahani DV. Cholangiocarcinoma: current and novel imaging techniques. Radiographics. 2008;28(5):1263–1287. doi:10.1148/rg.285075183.18794305
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, Chander A, et al. 18F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis. J Hepatol. 2019;71(1):115–129. doi:10.1016/j.jhep.2019.01.038.30797051
   PubMed Web of Science ®Google Scholar
• Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging. 2015;42(5):1165–1179. doi:10.1002/jmri.24810.25447417
   PubMed Web of Science ®Google Scholar
• Brandi G, Venturi M, Pantaleo MA, Ercolani G. Cholangiocarcinoma: current opinion on clinical practice diagnostic and therapeutic algorithms: a review of the literature and a long-standing experience of a referral center. Dig Liver Dis. 2016;48(3):231–241. doi:10.1016/j.dld.2015.11.01726769568
   PubMedGoogle Scholar
• Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428–444. doi:10.1016/S0140-6736(21)00153-733516341
   PubMed Web of Science ®Google Scholar
• Eloubeidi MA, Chen VK, Jhala NC, et al. Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma. Clin Gastroenterol Hepatol. 2004;2(3):209–213. doi:10.1016/s1542-3565(04)00005-915017604
   PubMed Web of Science ®Google Scholar
• Pereira P, Santos S, Morais R, et al. Role of peroral cholangioscopy for diagnosis and staging of biliary tumors. Dig Dis. 2020;38(5):431–440. doi:10.1159/000504910.31940612
   PubMed Web of Science ®Google Scholar
• Korrapati P, Ciolino J, Wani S, et al. The efficacy of peroral cholangioscopy for difficult bile duct stones and indeterminate strictures: a systematic review and meta-analysis. Endosc Int Open. 2016;04(03):E263–E275. doi:10.1055/s-0042-100194
   Google Scholar
• Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014;89(3):216–224. doi:10.1159/00036079124860985
   PubMed Web of Science ®Google Scholar
• Trikudanathan G, Navaneethan U, Njei B, Vargo JJ, Parsi MA. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79(5):783–789. doi:10.1016/j.gie.2013.09.01524140129
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Njei B, Venkatesh PG, Vargo JJ, Parsi MA. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79(6):943–950 e3. doi:10.1016/j.gie.2013.11.00124360654
   PubMed Web of Science ®Google Scholar
• Ferrone CR, Ting DT, Shahid M, et al. The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin RNA in situ hybridization technology. Ann Surg Oncol. 2016;23(1):290–296. doi:10.1245/s10434-014-4247-8.25519926
   PubMed Web of Science ®Google Scholar
• Kamp E, Dinjens WNM, Doukas M, et al. Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. Therap Adv Gastroenterol. 2021;14:17562848211002023. doi:10.1177/17562848211002023.
   Web of Science ®Google Scholar
• Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford). 2011;13(5):356–360. doi:10.1111/j.1477-2574.2011.00298.x.21492336
   PubMed Web of Science ®Google Scholar
• Huguet JM, Lobo M, Labrador JM, et al. Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases. 2019;7(14):1732–1752. doi:10.12998/wjcc.v7.i14.173231417920
   PubMed Web of Science ®Google Scholar
• Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Chin Clin Oncol. 2018;7(5):52. doi:10.21037/cco.2018.07.0330180751
   PubMed Web of Science ®Google Scholar
• Spolverato G, Bagante F, Weiss M, et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017;115(6):696–703. doi:10.1002/jso.2456928194791
   PubMed Web of Science ®Google Scholar
• Kang SH, Hwang S, Lee YJ, et al. Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2018;25(4):240–248. doi:10.1002/jhbp.54329450978
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388.28094848
   PubMed Web of Science ®Google Scholar
• Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215(1):31–38. doi:10.1097/00000658-199201000-00005.1309988
   PubMed Web of Science ®Google Scholar
• Matsuo K, Rocha FG, Ito K, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012;215(3):343–355. doi:10.1016/j.jamcollsurg.2012.05.025.22749003
   PubMed Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–4161. doi:10.1158/1078-0432.CCR-18-0078.29848569
   PubMed Web of Science ®Google Scholar
• Goldstein D, Lemech C, Valle J. New molecular and immunotherapeutic approaches in biliary cancer. ESMO Open. 2017;2(Suppl 1):e000152. doi:10.1136/esmoopen-2016-000152.28848675
   PubMed Web of Science ®Google Scholar
• Mahipal A, Tella SH, Kommalapati A, Anaya D, Kim R. FGFR2 genomic aberrations: achilles heel in the management of advanced cholangiocarcinoma. Cancer Treat Rev. 2019;78:1–7. doi:10.1016/j.ctrv.2019.06.003.31255945
   PubMed Web of Science ®Google Scholar
• Caparica R, Lengele A, Bekolo W, Hendlisz A. FOLFIRI as second-line treatment of metastatic biliary tract cancer patients. Autops Case Rep. 2019;9(2):e2019087. doi:10.4322/acr.2019.087.31528622
   PubMedGoogle Scholar
• Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–765. doi:10.21037/jgo.2019.03.10.31392056
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):541–565. doi:10.6004/jnccn.2021.0022.34030131
   PubMed Web of Science ®Google Scholar
• Golan T, Raitses-Gurevich M, Kelley RK, et al. Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study. Oncologist. 2017;22(7):804–810. doi:10.1634/theoncologist.2016-0415.28487467
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi:10.1016/S1470-2045(20)30445-9.32919526
   PubMed Web of Science ®Google Scholar
• Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491–1505. doi:10.1016/j.annonc.2020.07.014.32853681
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021;32:1111–1126. doi:10.1016/j.annonc.2021.04.012.33932504
   PubMed Web of Science ®Google Scholar
• Lamarca A, Kapacee Z, Breeze M, et al. Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med. 2020;9(9):2854. doi:10.3390/jcm9092854.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Wasan H, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27(1):134–140. doi:10.1093/annonc/mdv483.26483051
   PubMed Web of Science ®Google Scholar
• Plentz RR, Malek NP. Systemic therapy of cholangiocarcinoma. Visc Med. 2016;32(6):427–430. doi:10.1159/000453084.28229078
   PubMed Web of Science ®Google Scholar
• Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(12):1707–1712. doi:10.1001/jamaoncol.2018.3277.30178032
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. doi:10.1056/NEJMoa0908721.20375404
   PubMed Web of Science ®Google Scholar
• Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–474. doi:10.1038/sj.bjc.6605779.20628385
   PubMed Web of Science ®Google Scholar
• Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–830. doi:10.1001/jamaoncol.2019.0270.30998813
   PubMed Web of Science ®Google Scholar
• Sakai D, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol. 2018;29(suppl_8):viii205. doi:10.1093/annonc/mdy282.
   Google Scholar
• Phelip JM, Desrame J, Edeline J, et al. 52P modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: results of AMEBICA PRODIGE 38 randomized phase II trial. Ann Oncol. 2020;31:S260–S261. doi:10.1016/j.annonc.2020.08.030.
   Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690–701. doi:10.1016/S1470-2045(21)00027-9.33798493
   PubMed Web of Science ®Google Scholar
• Yoo C, Kim KP, Kim I, et al. Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): multicenter comparative randomized phase 2b study (NIFTY). J Clin Oncol. 2021;39(Suppl 15):abstr 4006.
   Web of Science ®Google Scholar
• Hyder O, Marsh JW, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20(12):3779–3786. doi:10.1245/s10434-013-3127-y.23846786
   PubMed Web of Science ®Google Scholar
• Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015;41(1):120–127. doi:10.1016/j.ejso.2014.09.007.25449754
   PubMed Web of Science ®Google Scholar
• Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34(5):460–468. doi:10.1200/JCO.2015.64.2710.26668346
   PubMed Web of Science ®Google Scholar
• Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):60–67. doi:10.1001/jamaoncol.2019.3718.31670750
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190–2198. doi:10.1002/ijc.33013.32359091
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733.28596308
   PubMed Web of Science ®Google Scholar
• Pembrolizumab in biliary tract cancer. Available from: https://ClinicalTrials.gov/show/NCT03260712. Accessed September 23, 2021.
   Google Scholar
• Durvalumab or placebo in combination with gemcitabine/cisplatin in patients with 1st line advanced biliary tract cancer (TOPAZ-1). Available from: https://ClinicalTrials.gov/show/NCT03875235. Accessed September 23, 2021.
   Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010. doi:10.1038/ng.3375.26258846
   PubMed Web of Science ®Google Scholar
• Seedor RS, Hall MJ. Germline Testing in Biliary Tract Cancers. Gastrointestinal Cancers Symposium: ASCO Daily News; 2019.
   Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807. doi:10.1016/S1470-2045(20)30157-1.32416072
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684. doi:10.1016/S1470-2045(20)30109-1.32203698
   PubMed Web of Science ®Google Scholar
• Crispo F, Pietrafesa M, Condelli V, et al. IDH1 targeting as a new potential option for intrahepatic cholangiocarcinoma treatment-current state and future perspectives. Molecules. 2020;25(16):3754. doi:10.3390/molecules25163754.
   PubMed Web of Science ®Google Scholar
• Wick A, Bahr O, Schuler M, et al. Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors. Clin Cancer Res. 2021;27(10):2723–2733. doi:10.1158/1078-0432.CCR-20-4256.33622704
   PubMed Web of Science ®Google Scholar
• Furuse J, Goyal L, Meric-Bernstam F, et al. 116MO - efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGF. ESMO Asia Virtual Congress 2020. Ann Oncol. 2020;31:S1287–S1318.
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282. doi:10.1200/JCO.2017.75.5009.29182496
   PubMed Web of Science ®Google Scholar
• Javle MM, Roychowdhury S, Kelley RK, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J Clin Oncol. 2021;39(3_suppl):265. doi:10.1200/JCO.2021.39.3_suppl.265.33503392
   PubMed Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–1079. doi:10.1158/2159-8290.CD-19-0182.31109923
   PubMed Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–282. doi:10.1016/S1470-2045(19)30691-6.31838007
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi:10.1056/NEJMoa1714448.29466156
   PubMed Web of Science ®Google Scholar
• Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54. doi:10.1016/S1470-2045(09)70333-X.19932054
   PubMed Web of Science ®Google Scholar
• Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010;28(21):3491–3497. doi:10.1200/JCO.2010.28.4075.20530271
   PubMed Web of Science ®Google Scholar
• Iyer RV, Pokuri VK, Groman A, et al. A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer. Am J Clin Oncol. 2018;41(7):649–655. doi:10.1097/COC.0000000000000347.27849649
   PubMed Web of Science ®Google Scholar
• Larsen FO, Markussen A, Diness LV, Nielsen D. Efficacy and safety of capecitabine, irinotecan, gemcitabine, and bevacizumab as second-line treatment in advanced biliary tract cancer: a phase II study. Oncology. 2018;94(1):19–24. doi:10.1159/000479970.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Rankin C, Siegel AB, et al. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014;110(4):882–887. doi:10.1038/bjc.2013.801.24423918
   PubMed Web of Science ®Google Scholar
• Moehler M, Maderer A, Schimanski C, et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer. 2014;50(18):3125–3135. doi:10.1016/j.ejca.2014.09.013.25446376
   PubMed Web of Science ®Google Scholar
• Lee JK, Capanu M, O’Reilly EM, et al. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer. 2013;109(4):915–919. doi:10.1038/bjc.2013.432.23900219
   PubMed Web of Science ®Google Scholar
• Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015;16(8):967–978. doi:10.1016/S1470-2045(15)00139-4.26179201
   PubMed Web of Science ®Google Scholar
• Santoro A, Gebbia V, Pressiani T, et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Ann Oncol. 2015;26(3):542–547. doi:10.1093/annonc/mdu576.25538178
   PubMed Web of Science ®Google Scholar
• Sun W, Patel A, Normolle D, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019;125(6):902–909. doi:10.1002/cncr.31872.30561756
   PubMed Web of Science ®Google Scholar
• Sohal DP, Mykulowycz K, Uehara T, et al. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol. 2013;24(12):3061–3065. doi:10.1093/annonc/mdt416.24146220
   PubMed Web of Science ®Google Scholar
• Chen JS, Hsu C, Chiang NJ, et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol. 2015;26(5):943–949. doi:10.1093/annonc/mdv035.25632066
   PubMed Web of Science ®Google Scholar
• Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–828. doi:10.1016/S1470-2045(14)70212-8.24852116
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–188. doi:10.1016/S1470-2045(11)70301-1.22192731
   PubMed Web of Science ®Google Scholar
• Vogel A, Kasper S, Bitzer M, et al. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. Eur J Cancer. 2018;92:11–19. doi:10.1016/j.ejca.2017.12.028.29413685
   PubMed Web of Science ®Google Scholar
• Javle MM, Hainsworth JD, Swanton C, et al. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from MyPathway. J Clin Oncol. 2017;35(4_suppl):402. doi:10.1200/JCO.2017.35.4_suppl.402.27893326
   PubMed Web of Science ®Google Scholar
• Jacobi O, Ross JS, Goshen-Lago T, et al. ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway. Oncol Res Treat. 2021;44(1–2):20–27. doi:10.1159/000511919.33279901
   PubMed Web of Science ®Google Scholar
• Ohba A, Morizane C, Ueno M, et al. Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. J Clin Oncol. 2020;38(15_suppl):TPS4654. doi:10.1200/JCO.2020.38.15_suppl.TPS4654.
   Web of Science ®Google Scholar
• Subbiah V, Lassen U, Elez E, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–1243. doi:10.1016/S1470-2045(20)30321-1.32818466
   PubMed Web of Science ®Google Scholar
• Goyal L, Zheng H, Yurgelun MB, et al. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017;123(11):1979–1988. doi:10.1002/cncr.30571.28192597
   PubMed Web of Science ®Google Scholar
• McNamara MG, Bridgewater JA, Palmer DH, et al. ABC-08: a phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers. J Clin Oncol. 2018;36(4_suppl):TPS544. doi:10.1200/JCO.2018.36.4_suppl.TPS544.
   Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165–171. doi:10.1038/s41416-018-0334-0.30420614
   PubMed Web of Science ®Google Scholar
• Javle MM, Oh D-Y, Ikeda M, et al. Results from TreeTopp: a randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC). J Clin Oncol. 2020;38(15_suppl):4597. doi:10.1200/JCO.2020.38.15_suppl.4597.
   Web of Science ®Google Scholar
• Peck J, Wei L, Zalupski M, O’Neil B, Villalona Calero M, Bekaii-Saab T. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology. 2012;82(3):175–179. doi:10.1159/000336488.22433475
   PubMed Web of Science ®Google Scholar
• Tan E, Kim DW, Mehta R, et al. Phase II study of copanlisib in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma. J Clin Oncol. 2020;38(4_suppl):556. doi:10.1200/JCO.2020.38.4_suppl.556
   Web of Science ®Google Scholar